Qazilbash et al developed a prognostic scoring system for a patient with chronic myeloid leukemia (CML) who receives an allogeneic stem cell transplant. This can help to identify patients who are most likely to benefit from the transplant. The authors are from MD Anderson Cancer Center in Houston.
Parameters:
(1) age of the recipient
(2) donor type
(3) donor and recipient genders
(4) interval between diagnosis of CML and transplant
(5) disease stage
Parameter |
Finding |
Points |
---|---|---|
age of the recipient |
< 20 years |
0 |
|
20 to 40 years |
1 |
|
> 40 years |
2 |
donor type |
HLA identical sibling |
0 |
|
matched unrelated |
1 |
donor and recipient genders |
female donor and male recipient |
1 |
|
all other |
0 |
interval from diagnosis |
< 12 months |
0 |
|
>= 12 months |
1 |
disease stage |
first chronic phase |
0 |
|
accelerated phase |
1 |
|
second or higher chronic phase |
2 |
|
blast crisis |
2 |
where:
• The choices for donor type may not include all options. In the implementation an HLA-identical sibling will be 0 and all others will be scored 1.
total score =
= SUM(points for all 5 parameters)
Interpretation:
• minimum score: 0
• maximum score: 7
• The higher the score the greater the risk for the patient.
Total Score |
Risk Group |
4 Year Overall Survival |
0 to 2 |
low |
53% |
3 to 7 |
high |
10.5% |
Purpose: To evaluate a patient with chronic myeloid leukemia (CML) for an allogeneic stem cell transplant using the prognostic score of Qazilbash et al.
Specialty: Clinical Laboratory, Hematology Oncology, Surgery, general
Objective: severity, prognosis, stage, complications, adverse effects, complication detection
ICD-10: Z52,